news
Pfizer brings frequent heartburn relief over-the-counter with new Nexium® 24HR
28 May 2014 | By Pfizer
The nation’s most prescribed acid blocker brand is now available without a prescription at retailers nationwide...
List view / Grid view
Pfizer
news
AstraZeneca Board rejects Pfizer’s final proposal
20 May 2014 | By AstraZeneca
The Board of AstraZeneca PLC notes the announcement by Pfizer Inc. of its final proposal, comprising £24.76 in cash (45%) and 1.747 Pfizer shares (55%) per AstraZeneca share, representing a value of £55.00 per AstraZeneca share (based on the closing price of Pfizer shares on 16 May 2014...
news
American College of Physicians, CECity, and Pfizer collaborate to increase adult immunization rates
16 May 2014 | By Pfizer
Public health initiative aims to increase unacceptably low adult vaccination rates...
news
Statement regarding Pfizer announcement
13 May 2014 | By Astrazeneca
The Board of AstraZeneca PLC notes the announcement made by Pfizer Inc. earlier...
news
Pfizer’s possible offer for AstraZeneca plc represents compelling shareholder value
13 May 2014 | By Pfizer
Pfizer is publishing a presentation to the shareholders of AstraZeneca on the merits of a combination of the two companies...
news
Pfizer confirms prior discussions with AstraZeneca regarding a possible combination and its continuing interest in a possible merger transaction
28 April 2014 | By Pfizer
This is an announcement of a possible offer falling under Rule 2.4 of the City Code on Takeovers and Mergers (the “Code”)...
news
Pfizer announces positive top-line results from two Phase 3 trials of Tofacitinib in adults with moderate-to-severe chronic plaque psoriasis
23 April 2014 | By Pfizer
Pfizer Inc. announced top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079)...
news
Pfizer’s novel CDK 4/6 inhibitor palbociclib plus letrozole significantly prolonged progression-free survival in patients with advanced breast cancer
7 April 2014 | By Pfizer
Final Phase 2 PALOMA-1 data to be presented for potential first-in-class palbociclib...
news
In a subanalysis, the benefits of eliquis® (apixaban) vs. Warfarin in reducing the risk of stroke in patients with nonvalvular atrial fibrillation were consistent, regardless of blood pressure control
27 March 2014 | By Bristol-Myers Squibb
Blood pressure control key factor in stroke risk...
news
Pfizer achieves primary endpoint with Phase 3b top-line results of GENOTROPIN® in very young children born small for gestational age
26 March 2014 | By Pfizer
Pfizer Inc. announced the top-line results from a Phase 3B study evaluating the 24-month efficacy of GENOTROPIN®...
news
Pfizer’s investigational vaccine candidate bivalent rLP2086 receives U.S. Food and Drug Administration breakthrough therapy designation for potential prevention of meningococcal B disease
20 March 2014 | By Pfizer Inc.
Pfizer intends to submit biologics license application for bivalent rLP2086 to U.S. Food and Drug Administration by mid-2014...
news
Pfizer launches 2013 integrated annual review
19 March 2014 | By Pfizer Inc
Pfizer Inc. announced the launch of its fourth integrated annual review, which summarizes the company’s 2013 financial, environmental and social responsibility performance...
news
Pfizer presents detailed results from landmark Community-Acquired Pneumonia immunization Trial in Adults evaluating efficacy of prevenar 13*
12 March 2014 | By Pfizer
Study findings, presented at ISPPD, demonstrate that prevenar 13 can prevent vaccine-type community-acquired pneumonia...
news
Pfizer will appeal court decision regarding Celebrex reissue patent
12 March 2014 | By Pfizer
Pfizer Inc. confirmed that the United States District Court for the Eastern District of Virginia granted summary judgment invalidating the reissue patent, covering methods of treating osteoarthritis and other approved conditions with celecoxib...
news
Pfizer announces positive top-line results of landmark community-acquired pneumonia immunization trial in adults evaluating efficacy of prevenar 13
24 February 2014 | By Pfizer
Pfizer Inc. announced that the Community-Acquired Pneumonia Immunization Trial in Adults achieved its primary clinical objective and both secondary clinical objectives...
